Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials. - Armstrong, April W.; Augustin, Matthias; Beaumont, Jennifer L.; Pham, Tan P.; Hudgens, Stacie; Gordon, Kenneth B.; Zhuo, Joe; Becker, Brandon; Zhong, Yichen; Kisa, Renata M.; Banerjee, Subhashis; Papp, Kim A. (Dermatology & Therapy, 2024)